Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to pursue well-validated but hard-to-drug targets, today announced that Joanne Kotz, Ph.D., Co-founder and Chief Executive Officer, will present a corporate overview at the 40^th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. ET.

About Jnana Therapeutics

Jnana Therapeutics is a biotechnology company utilizing its RAPID platform to address well-validated but hard-to-drug targets, including the solute carrier (SLC) family of metabolite transporters. Jnana is focused on developing best-in-class therapies to treat a wide range of diseases, including rare and immune-mediated diseases and cancer. Headquartered in Boston, Jnana is founded by world-renowned scientists and backed by leading life science investors. For more information, please visit www.jnanatx.com and follow us on Twitter and on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005325/en/